CN114652721A - 戊二酰亚胺衍生物用于克服类固醇抗性和治疗与异常干扰素γ信号传导相关的疾病的用途 - Google Patents

戊二酰亚胺衍生物用于克服类固醇抗性和治疗与异常干扰素γ信号传导相关的疾病的用途 Download PDF

Info

Publication number
CN114652721A
CN114652721A CN202210260820.9A CN202210260820A CN114652721A CN 114652721 A CN114652721 A CN 114652721A CN 202210260820 A CN202210260820 A CN 202210260820A CN 114652721 A CN114652721 A CN 114652721A
Authority
CN
China
Prior art keywords
compound
steroid
treatment
pharmaceutical composition
interferon gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210260820.9A
Other languages
English (en)
Chinese (zh)
Inventor
弗拉迪米尔·叶夫根尼耶维奇·涅博利辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemoimmunotherapy LLC
Original Assignee
Chemoimmunotherapy LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemoimmunotherapy LLC filed Critical Chemoimmunotherapy LLC
Publication of CN114652721A publication Critical patent/CN114652721A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210260820.9A 2018-11-23 2019-11-22 戊二酰亚胺衍生物用于克服类固醇抗性和治疗与异常干扰素γ信号传导相关的疾病的用途 Pending CN114652721A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
RU2018141291 2018-11-23
CN201980076564.4A CN113164464A (zh) 2018-11-23 2019-11-22 用于克服类固醇抗性的戊二酰亚胺衍生物
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980076564.4A Division CN113164464A (zh) 2018-11-23 2019-11-22 用于克服类固醇抗性的戊二酰亚胺衍生物

Publications (1)

Publication Number Publication Date
CN114652721A true CN114652721A (zh) 2022-06-24

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210260820.9A Pending CN114652721A (zh) 2018-11-23 2019-11-22 戊二酰亚胺衍生物用于克服类固醇抗性和治疗与异常干扰素γ信号传导相关的疾病的用途
CN201980076564.4A Pending CN113164464A (zh) 2018-11-23 2019-11-22 用于克服类固醇抗性的戊二酰亚胺衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980076564.4A Pending CN113164464A (zh) 2018-11-23 2019-11-22 用于克服类固醇抗性的戊二酰亚胺衍生物

Country Status (19)

Country Link
US (1) US20220362230A1 (https=)
EP (2) EP4218758A3 (https=)
JP (2) JP2022508167A (https=)
KR (2) KR20220162821A (https=)
CN (2) CN114652721A (https=)
AU (2) AU2019384626A1 (https=)
BR (1) BR112021009801A2 (https=)
CA (1) CA3120882A1 (https=)
CL (2) CL2021001316A1 (https=)
EA (1) EA201992646A1 (https=)
GE (4) GEAP202215712A (https=)
IL (2) IL297533A (https=)
MD (2) MD4844C1 (https=)
MX (2) MX2021006032A (https=)
MY (1) MY209416A (https=)
PH (1) PH12021551152A1 (https=)
RU (1) RU2712281C1 (https=)
WO (1) WO2020106191A1 (https=)
ZA (2) ZA202104247B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
CN105722511A (zh) * 2013-11-14 2016-06-29 制药有限责任公司 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
CN105722511A (zh) * 2013-11-14 2016-06-29 制药有限责任公司 包含戊二酰亚胺衍生物的药物组合物及其用于治疗嗜酸细胞性疾病的用途
US20160279114A1 (en) * 2013-11-14 2016-09-29 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

Also Published As

Publication number Publication date
MD20210050A2 (ro) 2021-12-31
WO2020106191A1 (ru) 2020-05-28
EP4218758A2 (en) 2023-08-02
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MD4851B1 (ro) 2023-04-30
PH12021551152A1 (en) 2021-10-25
GEP20237467B (en) 2023-02-10
MD4844C1 (ro) 2023-09-30
MD4844B1 (ro) 2023-02-28
AU2019384626A1 (en) 2021-07-15
IL283317A (en) 2021-07-29
ZA202210444B (en) 2023-01-25
MX2022013503A (es) 2022-11-16
EP4218758A3 (en) 2023-08-23
JP2023015333A (ja) 2023-01-31
EP3884945A1 (en) 2021-09-29
CA3120882A1 (en) 2020-05-28
IL297533A (en) 2022-12-01
AU2022256212A1 (en) 2022-12-08
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
CL2022000683A1 (es) 2022-10-28
RU2712281C1 (ru) 2020-01-28
CN113164464A (zh) 2021-07-23
CL2021001316A1 (es) 2021-10-29
GEP20247643B (en) 2024-07-10
EA201992646A1 (ru) 2020-05-31
MX2021006032A (es) 2021-07-06
KR20210095652A (ko) 2021-08-02
MY209416A (en) 2025-07-08
US20220362230A1 (en) 2022-11-17
AU2022256212B2 (en) 2024-08-15
GEAP202215712A (en) 2022-10-10
GEAP202415619A (en) 2024-03-11
ZA202104247B (en) 2023-03-29
BR112021009801A2 (pt) 2022-03-03
EP3884945A4 (en) 2022-11-23
MD20210032A2 (ro) 2021-09-30

Similar Documents

Publication Publication Date Title
US8178509B2 (en) Method to treat sickle cell disease
AU2014249456B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
RS59490B1 (sr) Sublingvalna formulacija riluzola
JP7518997B2 (ja) ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
JP2026065136A (ja) 症候性ウイルス疾患の処置
EA015404B1 (ru) Применение эсцина
JP2005508983A (ja) Ｐｄｅ４又はｐｄｅ３／４阻害剤及び抗リウマチ薬の複合薬
US20090247558A1 (en) Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases
US11439631B2 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
HK40074427A (en) USE OF GLUTARIMIDE DERIVATIVES FOR OVERCOMING STEROID RESISTANCE AND TREATING DISEASES ASSOCIATED WITH ABERRANT INTERFERON γ SIGNALING
CN102470125B (zh) 苄达明在制备治疗p40-依赖性疾病的药物中的用途
HK40059361A (en) Glutarimide derivative for overcoming resistance to steriods
OA20833A (en) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
JP2020536929A (ja) Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EA046267B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EP4703368A1 (en) Isolithocholic acid derivatives and use thereof
US20250352563A1 (en) Method and Use of Psilocybin in the Prevention and Treatment of Stroke
JP2001512446A (ja) メラニンによるサイトカインの調整
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
CN114502167A (zh) 用于治疗失眠的药物组合物
JP2014201577A (ja) アレルギー性疾患の予防または治療のための医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074427

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220624